DXB Stock Overview
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs.
Dimerix Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.17|
|52 Week High||AU$0.29|
|52 Week Low||AU$0.12|
|1 Month Change||6.25%|
|3 Month Change||9.68%|
|1 Year Change||-29.17%|
|3 Year Change||36.00%|
|5 Year Change||36.00%|
|Change since IPO||-15.00%|
Recent News & Updates
We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn RateSep 16
We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn RateJun 02
Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO CompensationSep 20
Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?May 17
Here's What We Think About Dimerix's (ASX:DXB) CEO PayFeb 01
|DXB||AU Biotechs||AU Market|
Return vs Industry: DXB underperformed the Australian Biotechs industry which returned -4.4% over the past year.
Return vs Market: DXB underperformed the Australian Market which returned -2% over the past year.
|DXB Average Weekly Movement||11.4%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||9.0%|
|10% most volatile stocks in AU Market||16.0%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: DXB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: DXB's weekly volatility (11%) has been stable over the past year.
About the Company
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.
Dimerix Limited Fundamentals Summary
|DXB fundamental statistics|
Is DXB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DXB income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.033|
|Net Profit Margin||-162.25%|
How did DXB perform over the long term?See historical performance and comparison